Published in Bioinformatics on May 08, 2006
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform (2009) 1.98
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res (2008) 1.54
A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia (2008) 1.35
A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics (2012) 1.26
Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer (2010) 1.22
Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. BMC Bioinformatics (2010) 1.16
Increased entropy of signal transduction in the cancer metastasis phenotype. BMC Syst Biol (2010) 1.16
Bimodal gene expression patterns in breast cancer. BMC Genomics (2010) 1.07
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 1.01
SIBER: systematic identification of bimodally expressed genes using RNAseq data. Bioinformatics (2013) 1.00
Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics (2009) 0.97
A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia (2011) 0.97
DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference. BMC Bioinformatics (2011) 0.91
Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia (2012) 0.89
Common germ-line polymorphism of C1QA and breast cancer survival. Br J Cancer (2010) 0.87
Gene-sharing networks reveal organizing principles of transcriptomes in Arabidopsis and other multicellular organisms. Plant Cell (2012) 0.87
Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res (2012) 0.85
The most informative spacing test effectively discovers biologically relevant outliers or multiple modes in expression. Bioinformatics (2014) 0.84
Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget (2016) 0.81
An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations. PLoS One (2013) 0.80
MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphisms. BMC Genomics (2011) 0.80
A peculiar mutation spectrum emerging from young peruvian patients with hepatocellular carcinoma. PLoS One (2014) 0.78
Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer. Genome Biol (2015) 0.78
Detection of patient subgroups with differential expression in omics data: a comprehensive comparison of univariate measures. PLoS One (2013) 0.75
Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One (2013) 0.75
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine. BMC Genomics (2016) 0.75
C1orf64 is a novel androgen receptor target gene and coregulator that interacts with 14-3-3 protein in breast cancer. Oncotarget (2017) 0.75
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
Species-specific transcription in mice carrying human chromosome 21. Science (2008) 4.03
Statistical issues in the analysis of Illumina data. BMC Bioinformatics (2008) 3.66
ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res (2006) 3.60
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
p300/CBP and cancer. Oncogene (2004) 3.13
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. Nature (2013) 2.49
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep (2007) 2.17
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer (2008) 2.11
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene (2005) 2.05
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol (2010) 2.01
Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res (2012) 1.95
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer (2008) 1.76
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74
Cancer genetics of epigenetic genes. Hum Mol Genet (2007) 1.72
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res (2006) 1.71
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol (2010) 1.68
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer (2005) 1.62
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol (2004) 1.59
Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009) 1.58
The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics (2009) 1.55
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res (2010) 1.55
A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res (2008) 1.54
p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci U S A (2004) 1.53
Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol (2007) 1.51
Tissue-specific splicing factor gene expression signatures. Nucleic Acids Res (2008) 1.49
Genome-wide identification of functionally distinct subsets of cellular mRNAs associated with two nucleocytoplasmic-shuttling mammalian splicing factors. Genome Biol (2006) 1.49
A new genome-driven integrated classification of breast cancer and its implications. EMBO J (2013) 1.47
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat (2002) 1.44
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology (2010) 1.43
Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol (2003) 1.43
Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res (2009) 1.42
Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet (2003) 1.42
Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci U S A (2007) 1.41
The 17q23 amplicon and breast cancer. Breast Cancer Res Treat (2003) 1.40
Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics (2006) 1.39
Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet (2009) 1.39
Fine scale mapping of the breast cancer 16q12 locus. Hum Mol Genet (2010) 1.39
Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol (2014) 1.38
Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays. Appl Immunohistochem Mol Morphol (2016) 1.38
Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput Biol (2007) 1.36
A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. Bioinformatics (2005) 1.36
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.33
BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res (2007) 1.33
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res (2006) 1.31
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res (2010) 1.31
Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res (2011) 1.29
Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res (2008) 1.28
Spike-in validation of an Illumina-specific variance-stabilizing transformation. BMC Res Notes (2008) 1.28
TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer. Nat Commun (2012) 1.23
A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol (2011) 1.23